eg ask if a new drug company/startup will generate positive returns for its investors
1 Like
You must provide personal information and after the $20.00 no cost credit you receive you have to purchase more to use.
1 Like
I asked it about generalproximity (hopefully generalproximity does better!!)
Will General Proximity Bio (generalproximity.bio) generate positive returns for its investors?
âś“
researchers 1-3
probability: 31%
rationale: At 31%, this probability reflects a company that stands out significantly from typical seed-stage peers due to exceptional early validation, but remains constrained by the unforgiving failure rates and structural hurdles of preclinical biopharma.
There are strong positive signals that elevate General Proximity Bio above the generic 10–15% base rate for positive-return biotech exits. Since emerging from stealth in January 2025 with $16M raised (backed by Felicis and Y Combinator)
, the company has maintained excellent momentum. In early 2026, it closed a 2x-oversubscribed $12M pre-Series A round
and secured a strategic investment from Daewoong/FreeMind
, bringing total equity raised to approximately $28M. Third-party scientific validation is unusually robust for this stage, anchored by a multi-target oncology collaboration with Daiichi Sankyo
and significant non-dilutive funding, including a $3M ARPA-H Sprint for Women’s Health award
and a $400k NCI SBIR Phase I grant
. Because the total capital raised is still relatively modest, even a smaller platform acquisition ($50M–$100M) could currently clear the hurdle to return positive yields to early investors.However, the structural and scientific realities of early-stage biotech cap the probability well below even odds. The company remains highly preclinical , with no disclosed IND, clinical data, or lead asset. While the induced-proximity space is highly promising and has seen clinical validation, severe technical risks remain around selectivity, pharmacokinetics, oral bioavailability, and off-target effects
.Furthermore, some of the early validation signals are “soft”: five “Golden Ticket” pharma awards are essentially incubator perks, and the financial terms of the Daiichi Sankyo partnership remain undisclosed, suggesting it may currently be more exploratory than financially material.
Crucially, the mechanics of the resolution criteria present a long-term headwind. A positive resolution requires an exit above the total capital raised—a bar that will continue to rise as the company consumes capital and raises future dilutive rounds. Most platform biotechs at this stage either fail outright or stall in a non-liquidating “zombie” state
. Balancing the company’s top-quartile traction against the demanding, unbounded horizon for a net-positive liquidity event yields an estimate in the low 30s.
You have better opportunity in Lost Wages{Las Vegas, NV].
You really use a “free”{not really free as you are the product] AI system to make financial decisions?
It’s actually a pretty cool website. And you can just sign up with another email if you really wanted to use it again after the $20 free credit is used up.
I’m running an analysis of an Australian biotech company I’ve been following for a short while and its way of thinking is definitely more than surface level.
It shows its thinking process, all domains it references. It seems to use multiple agents simultaneously.
Also, this isn’t just for financial decisions, if it is accurate it could predict how likely a company working on a particular intervention is to be successful.
It’s also just really cool to see something work like this. Quite promising for the future of AI research tools imo.
I did a purely financial analysis of the company I’ve been following. It painted a grim picture that I honestly expected.
I now tasked it with the following question:
“Given the data that has come out so far for all of their drug assets, and given their currently pipeline and timeline for each drugs upcoming trials, if they manage to go ahead as planned and each trial is successful to the ends they are going for, what are the implications of this not only for investors but for human health/longevity?”
I still really like michael d forrest, but the world is harsh 
Will quadraScope Venture Fund I return positive to investors (DPI > 1x or net positive IRR)?
âś“
researchers 1-3
probability: 31%
rationale: quadraScope Venture Fund I is a very small, first-time longevity-biotech micro-VC, with an SEC Form D indicating a $4.48M total offering
. Investing exclusively in early-stage age reversal and disease prevention via small checks typically ranging from $100K to $300K
, the fund faces a steep structural climb to return its capital, offset by above-average early clinical traction in its portfolio. Recent venture base rates argue for caution: by Q1 2026, less than 20% of 2017-2018 vintage funds had reached 1x realized cash distributions (DPI)
, and first-time, single-sector biotech funds carry a high failure rate. Despite these headwinds, the portfolio has accumulated multiple concrete milestones. Immunis raised a $25M Series A-1 and reported preliminary Phase 2 gait-speed improvements
, Matter Bio received FDA IND clearance for a pancreatic-cancer trial
, Repair Biotechnologies secured FDA orphan-drug designation
, Vincere received a $5M Michael J. Fox Foundation award
, ADvantage achieved EU Phase 2 approvals and UK ILAP status
, and Turn Biotechnologies saw an asset acquisition by Daewoong
. Because the fund is only ~$4.5M, a single strong M&A event or IPO could theoretically return the entire vehicle. However, translating this paper progress into cash distributions by 2035 remains a significant hurdle. In biotech, attrition from early clinical stages to approval or exit is notoriously high. More importantly, quadraScope’s tiny initial checks will suffer extreme equity dilution across subsequent, capital-intensive financing rounds. If the fund holds 1% or less of a company at exit, returning >$4.5M to LPs net of fees would require roughly $500M in aggregate exit value-a high bar in a speculative longevity sector where aging is not an FDA-approvable indication. The 31% estimate balances these forces: the fund’s undeniable clinical and regulatory progress elevates its chances above a generic micro-fund, but the severe dilution, binary biotech risks, and the strict requirement for realized cash (rather than paper markups) keep the likelihood of a net-positive DPI below a coin flip.
1 Like